Navigation Links
AEterna Zentaris Closes Sale of Cetrotide(R) Royalty Stream for $52.5 Million to Cowen Healthcare Royalty Partners
Date:12/3/2008

All amounts are in U.S. dollars

QUEBEC CITY, Dec. 3 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS; TSX: AEZ), a global biopharmaceutical company focused on endocrine therapy and oncology, announces that it has completed the transaction under the previously announced purchase and sale agreement with Cowen Healthcare Royalty Partners, L.P. ("CHRP") relating to AEterna Zentaris' rights to royalties on future sales of Cetrotide(R) covered by its license agreement with Merck Serono. AEterna Zentaris received $52.5 million from CHRP at closing, less certain transaction costs. Under the terms of the agreement with CHRP, AEterna Zentaris would receive an additional payment of $2.5 million from CHRP contingent on 2010 net sales of Cetrotide(R) reaching a specified level.

About Cetrotide(R) (cetrorelix)

Cetrotide(R) (cetrorelix) was the first luteinizing hormone-releasing hormone (LHRH) antagonist treatment approved for in vitro fertilization. It is administered to women to prevent premature ovulation in order to increase fertility success rate. Developed in cooperation with Medicine Nobel-Prize winner, Professor Andrew Schally of Veterans Affairs, Miami, Florida, it was launched in Europe in 1999 and in the United States in 2001. Cetrotide(R) is currently marketed worldwide by Merck Serono, except for Japan where it is marketed by Nippon Kayaku and Shionogi.

Cetrorelix is also currently in a Phase 3 program in benign prostatic hyperplasia involving 1,500 patients in North America and Europe. First results are expected in Q3 2009 with an NDA filing to follow in 2010 and potential launch in 2011.

About Cowen Healthcare Royalty Partners

Cowen Healthcare Royalty Partners ("CHRP") is a global healthcare private equity firm with over $500 million in capita
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
2. AEterna Zentaris to Present at Upcoming UBS Global Life Sciences Conference in New York
3. AEterna Zentaris Announces Outcome of Managements Strategic Review
4. AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment
5. AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers
6. AEterna Zentaris to Present at the Upcoming Roth Capital Partners 20th Annual OC Growth Stock Conference in Dana Point, California
7. Aeterna Zentaris to Announce Fourth Quarter and Full-Year 2007 Financial and Operating Results on March 5, 2008
8. AEterna Zentaris Announces the Departure of SVP, Administrative and Legal Affairs
9. AEterna Zentaris and Paladin Labs Announce Sale and Purchase of Miltefosine Rights
10. Aeterna Zentaris Reports Fourth Quarter and Full-Year 2007 Financial and Operating Results
11. Aeterna Zentaris Begins Second Phase 3 Trial of Cetrorelix for Benign Prostatic Hyperplasia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... -- Technology Applications International Corporation (the "Company" or "NUUU")(OTC BB: ... Inc. has signed an additional exclusive licensing agreement with ... Johnson Space Center in Houston , ... Charles J. Scimeca , NUUU,s ... latest, exclusive agreement with NASA. In addition to our ...
(Date:9/2/2014)... , Sept. 2, 2014 Orexigen Therapeutics, ... the U.S. Patent and Trademark Office (PTO) has issued ... being evaluated for weight loss. NB32 is a fixed-dose ... U.S. Patent No. 8,815,889 claims methods for ... bupropion. The patent expires in 2024. If NB32 is ...
(Date:9/2/2014)... Md. , Sept. 2, 2014  Synthetic ... novel anti-infective biologic and drug candidates targeting specific ... today positive results from its final preclinical toxicology ... Administration (FDA) guidance, this bridging study was required ... candidate designed to prevent the devastating effects of ...
(Date:9/2/2014)... , Sept. 2, 2014  Spherix Incorporated (SPEX) -- an ... monetization of intellectual property, today announced that the United ... to the Company in the month of August that ... The issued patents are: ... U.S.RE45,081 issued August 19, 2014; and , U.S.RE45,095 ...
Breaking Biology Technology:Technology Applications International Corporation Subsidiary Enters Into Additional Exclusive Agreement with NASA at a Signing Ceremony at the Johnson Space Center In Houston, Texas 2Technology Applications International Corporation Subsidiary Enters Into Additional Exclusive Agreement with NASA at a Signing Ceremony at the Johnson Space Center In Houston, Texas 3Orexigen Expands NB32 Intellectual Property Portfolio With New U.S. Patent 2Orexigen Expands NB32 Intellectual Property Portfolio With New U.S. Patent 3Orexigen Expands NB32 Intellectual Property Portfolio With New U.S. Patent 4Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 2Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 3Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 4Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 5United States Patent & Trademark Office Issues Three New Standard Essential Patents to Spherix 2
... 13 Proteon Therapeutics is,presenting new data ... potential of PRT-201 to enhance outcomes in ... (PAD). The,presentation, entitled, "Local Catheter-Directed Elastase Therapy: ... is being made at the 20th,annual Transcatheter ...
... CLARA, Calif., Oct. 13 WebLOQ, Inc., ... secure and compliant eBusiness and,data-in-motion communications, today ... the WebLOQ ePrivacy solution in their state-of-the-art,Monterey ... partner, the,Monterey Peninsula Surgery Center, and other ...
... SYDNEY, Australia, Oct. 13 /Xinhua-PRNewswire-FirstCall/ -- Pharmaxis,Ltd (AXS: ... Quarterly,Report to Shareholders on the afternoon of Wednesday ... teleconference the following morning to,review the quarter and ... on Thursday 16th October at 8.30am (Sydney),(Wednesday 15th ...
Cached Biology Technology:Proteon Therapeutics to Present New Data on PRT-201 at Transcatheter Cardiovascular Therapeutics (TCT) Annual Symposium in Washington, D.C., October 13, 2008 2Monterey Spine and Joint Deploys WebLOQ ePrivacy Solution for HIPAA Compliant Health Information Exchange 2Monterey Spine and Joint Deploys WebLOQ ePrivacy Solution for HIPAA Compliant Health Information Exchange 3
(Date:9/2/2014)... may have discovered a new way of harnessing lupus ... DNA repair. , The findings were published recently in ... study, led by James E. Hansen, M.D., assistant professor ... that cancer cells with deficient DNA repair mechanisms (or ... significantly more vulnerable to attack by lupus antibodies. , ...
(Date:9/2/2014)... true that digital distribution of media will have ... at least when file sizes are large. , ... Yale,s Journal of Industrial Ecology that ... consoles such as PlayStation3. Researchers found that Blu-ray ... gas emissions than game files downloaded over broadband ...
(Date:9/2/2014)... 2, 2014 In a new study that could ... Florida campus of The Scripps Research Institute (TSRI) have ... unique manufacturing sites for molecules that can treat a ... as a reaction vessel and a disease-causing defect as ... cell," said TSRI Professor Matthew Disney.,"Because the treatment is ...
Breaking Biology News(10 mins):Sabotage as therapy: Aiming lupus antibodies at vulnerable cancer cells 2Scripps Florida scientists make diseased cells synthesize their own drug 2
... theoretical price of having one's personal genome sequenced just ... $2.2 million, and the goal is to reduce the ... realistic. , The sharp drop is due to a ... (HMS) researchers Jay Shendure, Gregory Porreca, George Church, and ...
... form of a powerful painkiller for a quick and dangerous ... alarm as the number of people dying from an overdose ... than morphine, rises. , Addicts are misusing a clear patch ... into the bloodstream over the course of a few days, ...
... with a Global Information System will provide valuable information ... National Institute of Environmental Health Sciences (NIEHS), one of ... provide the most up-to-date data to public health and ... industry maps, as well as demographic information for local ...
Cached Biology News:A step toward the $1,000 personal genome using readily available lab equipment 2Prescription pain patch abuse blamed for increase in deaths 2Prescription pain patch abuse blamed for increase in deaths 3FDA approves child-friendly AIDS medicine 2
... High-throughput protein crystallography involves using many ... Screening (HTS). The liquid handling requirements are ... volume: traditional crystallography plates have 24 or ... of microliters. For higher throughput, the number ...
... Description: ,Kit containing Dermal Fibroblasts (Mouse/BalbC) ... as a long-term culture, and is guaranteed ... continuous growth from the date supplied, when ... Dermis, mouse/BalbC, embryonic day 18.5 ,Applications: ...
... designed for protein pull-down experiments ... binding proteins. An order of ... agarose beads with 10 nmol ... terminus of the alkyl chain; ...
Rabbit polyclonal to Staphylococcus Enterotoxin A (HRP) ( Abpromise for all tested applications)....
Biology Products: